Montelukast for bronchiolitis obliterans syndrome after lung transplantation: A pilot study

Transplant International

Volumn 24, Issue 7, 2011, Pages 651-656

  Verleden, Geert M ^a   Verleden, Stijn E ^b   Vos, Robin ^b   De Vleeschauwer, Stéphanie I ^b   Dupont, Lieven J ^a   Van Raemdonck, Dirk E ^a   Vanaudenaerde, Bart M ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Bronchiolitis obliterans syndrome; Chronic rejection; Lung transplantation; Montelukast

Indexed keywords

AZATHIOPRINE; AZITHROMYCIN; CYCLOSPORIN; CYCLOSPORIN A; MONTELUKAST; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ADD ON THERAPY; ADULT; ARTICLE; BRONCHIOLITIS OBLITERANS; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; GRAFT DYSFUNCTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG GRAFT REJECTION; LUNG LAVAGE; LUNG TRANSPLANTATION; MALE; NEUTROPHILIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION;

ACETATES; AZITHROMYCIN; BRONCHIOLITIS OBLITERANS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LEUKOTRIENE ANTAGONISTS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PILOT PROJECTS; QUINOLINES; TREATMENT OUTCOME;

EID: 79959845442     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2011.01248.x     Document Type: Article

References (24)

1. Christie JD, Edwards LB, Aurora P, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-sixth Official Adult Lung and Heart-Lung Transplantation Report - 2009. J Heart Lung Transplant 2009; 28: 1031.
2. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297.
3. Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007; 26: 1229.
4. Verleden GM, Vos R, De Vleeschauwer SI, et al. Obliterative bronchiolitis following lung transplantation: from old to new concepts? Transpl Int 2009; 22: 771.
5. Gerhardt SG, McDyer JF, Girgis RE, Conte JV, Yang SC, Orens JB. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med 2003; 168: 121.
6. Vanaudenaerde BM, Vos R, Meyts I, et al. Macrolide therapy targets a specific phenotype in respiratory medicine: from clinical experience to basic science and back. Inflamm Allergy Drug Targets 2008; 7: 279.
7. Benden C, Boehler A. Long-term clarithromycin therapy in the management of lung transplant recipients. Transplantation 2009; 87: 1538.
8. Vanaudenaerde BM, Meyts I, Vos R, et al. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J 2008; 32: 832.
9. Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2006; 174: 566.
10. Gottlieb J, Szangolies J, Koehnlein T, Golpon H, Simon A, Welte T. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2008; 85: 36.
11. Vos R, Vanaudenaerde BM, Verleden SE, et al. A randomized placebo-controlled trial of azithromycin to prevent bronchiolitis obliterans syndrome after lung transplantation. Eur Respir J 2011; 37: 164.
12. Sarahrudi K, Estenne M, Corris P, et al. International experience with conversion from cyclosporine to tacrolimus for acute and chronic lung allograft rejection. J Thorac Cardiovasc Surg 2004; 127: 1126.
13. Vos R, Vanaudenaerde BM, Ottevaere A, et al. Long-term azithromycin for bronchiolitis obliterans syndrome: divide and conquer? J Heart Lung Transplant 2010; 29: 1358.
14. Ramsay CF, Sullivan P, Gizycki M, et al. Montelukast and bronchial inflammation in asthma: a randomised, double-blind placebo-controlled trial. Respir Med 2009; 103: 995.
15. Izumo T, Kondo M, Nagai A. Cysteinyl-leukotriene 1 receptor antagonist attenuates bleomycin-induced pulmonary fibrosis in mice. Life Sci 2007; 80: 1882.
16. El-Swefy S, Hassanen SI. Improvement of hepatic fibrosis by leukotriene inhibition in cholestatic rats. Ann Hepatol 2009; 8: 41.
17. Or R, Gesundheit B, Resnick I, et al. Sparing effect by montelukast treatment for chronic graft versus host disease: a pilot study. Transplantation 2007; 83: 577.
18. Verleden GM, Lievens Y, Dupont LJ, et al. Efficacy of total lymphoid irradiation in azithromycin nonresponsive chronic allograft rejection after lung transplantation. Transplant Proc 2009; 41: 1816.
19. Fisher AJ, Rutherford RM, Bozzino J, Parry G, Dark JH, Corris PA. The safety and efficacy of total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant 2005; 5: 537.
20. Morrell MR, Despotis GJ, Lublion DM, Patterson GA, Trulock EP, Hachem RR. The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant 2010; 29: 424.
21. Lama VN, Murray S, Lonigro RJ, et al. Course of FEV(1) after onset of bronchiolitis obliterans syndrome in lung transplant recipients. Am J Respir Crit Care Med 2007; 175: 1192.
22. Joos S, Miksch A, Szecsenyi J, et al. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. Thorax 2008; 63: 453.
23. Mehrotra AK, Henderson Jr WR. The role of leukotrienes in airway remodeling. Curr Mol Med 2009; 9: 383.
24. Yoshisue H, Kirkham-Brown J, Healy E, Holgate ST, Sampson AP, Davies DE. Cysteinyl leukotrienes synergize with growth factors to induce proliferation of human bronchial fibroblasts. J Allergy Clin Immunol 2007; 119: 132.